Legal & General Group Plc Buys 1,339 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Legal & General Group Plc lifted its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 57,753 shares of the medical instruments supplier’s stock after purchasing an additional 1,339 shares during the period. Legal & General Group Plc owned 0.26% of LeMaitre Vascular worth $5,321,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. New York State Teachers Retirement System raised its holdings in LeMaitre Vascular by 1.2% in the 4th quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier’s stock valued at $755,000 after acquiring an additional 100 shares in the last quarter. Flputnam Investment Management Co. grew its holdings in LeMaitre Vascular by 3.6% during the 4th quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock worth $269,000 after acquiring an additional 102 shares during the last quarter. Norden Group LLC increased its holdings in shares of LeMaitre Vascular by 4.5% in the fourth quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock valued at $218,000 after purchasing an additional 103 shares in the last quarter. Blue Barn Wealth LLC increased its stake in shares of LeMaitre Vascular by 4.4% in the 4th quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock valued at $229,000 after buying an additional 104 shares during the period. Finally, Shaker Investments LLC OH increased its position in LeMaitre Vascular by 0.8% in the fourth quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock worth $1,285,000 after purchasing an additional 112 shares during the period. 84.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

LMAT has been the subject of several recent research reports. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price target for the company. Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Finally, Lake Street Capital boosted their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and an average price target of $95.25.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company’s stock, valued at $456,915.68. This trade represents a 26.53 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Trading Up 1.9 %

Shares of LMAT opened at $86.28 on Monday. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of 47.15, a PEG ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 12 month low of $62.40 and a 12 month high of $109.58. The firm has a fifty day simple moving average of $87.85 and a 200 day simple moving average of $93.52.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting analysts’ consensus estimates of $0.49. The company had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. As a group, research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.93%. The ex-dividend date of this dividend was Thursday, March 13th. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.16. LeMaitre Vascular’s dividend payout ratio is presently 41.24%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.